|
|
Abstracts and Articles Discuss Surgical Implants Coated with One of 'Nature's Antibiotics' Could Prevent Infection in the Main forums forums; Surgical implants coated with one of 'nature's antibiotics' could prevent infection 1st on the web (February 3, 2009) February ... |
|
LinkBack | Thread Tools | Display Modes |
|
||||
Surgical Implants Coated with One of 'Nature's Antibiotics' Could Prevent Infection
Surgical implants coated with one of 'nature's antibiotics' could prevent infection
1st on the web (February 3, 2009) February 2009 Researchers at the University of British Columbia have discovered a mimic of one of "nature's antibiotics" that can be used to coat medical devices to prevent infection and rejection. The study, published in the Jan. 30 issue of Chemistry & Biology, found that a synthetic form – short tethered cationic antimicrobial peptides (cationic peptide) – can protect surfaces, killing bacteria and fungi that come into contact with them. The discovery could lead to new protection for surgical implants, catheters, hip replacements and joint prostheses. “The rapid progress of biomedical technology and an aging population places increasing demands on medical implants to treat serious tissue disorders and replace organ function,” Robert Hancock, principal investigator and Canada Research Chair in Pathogenomics and Antimicrobials at UBC’s Department of Microbiology and Immunology, said in a press release. “These cationic peptides are currently being developed as soluble antibiotics for administration to patients to combat infection. We have developed a new method for finding a variety of effective peptides that can bind to a surface and still kill harmful bacteria and fungus.” Link _____________________________________ Chemistry & Biology Volume 16, Issue 1, 30 January 2009, Pages 58-69 Screening and Characterization of Surface-Tethered Cationic Peptides for Antimicrobial Activity Kai Hilpert1, 6, Melissa Elliott1, Håvard Jenssen1, Jason Kindrachuk1, Christopher D. Fjell1, Jana Körner2, Dirk F.H. Winkler3, Lindsay L. Weaver4, Peter Henklein5, Anne S. Ulrich6, Sandy H.Y. Chiang1, Susan W. Farmer1, Nelly Pante4, Rudolf Volkmer2 and Robert E.W. Hancock1, , 1. Centre for Microbial Diseases and Immunity Research, University of British Columbia, 2259 Lower Mall Research Station, Vancouver, BC V6T 1Z3, Canada 2. Institut für Medizinische Immunologie, Universitätsklinikum Charité, Humboldt-Universität zu Berlin, Hessische Str. 3-4, 10117 Berlin, Germany 3. Peptide Array Facility of the Brain Research Centre, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada 4. Department of Zoology, University of British Columbia, 6270 University Boulevard, Vancouver, BC V6T 1Z4, Canada 5. Institut für Biochemie, Universitätsklinikum Charité, Humboldt-Universität zu Berlin, Monbijoustrasse 2, 10117 Berlin, Germany 6. Karlsruhe Institute of Technology, Institute of Biological Interfaces, POB 3640, 76021 Karlsruhe, Germany Summary There is an urgent need to coat the surfaces of medical devices, including implants, with antimicrobial agents to reduce the risk of infection. A peptide array technology was modified to permit the screening of short peptides for antimicrobial activity while tethered to a surface. Cellulose-amino-hydroxypropyl ether (CAPE) linker chemistry was used to synthesize, on a cellulose support, peptides that remained covalently bound during biological assays. Among 122 tested sequences, the best surface-tethered 9-, 12-, and 13-mer peptides were found to be highly antimicrobial against bacteria and fungi, as confirmed using alternative surface materials and coupling strategies as well as coupling through the C and N termini of the peptides. Structure-activity modeling of the structural features determining the activity of tethered peptides indicated that the extent and positioning of positive charges and hydrophobic residues were influential in determining activity. Author Keywords: CHEMBIO; MICROBIO Copyright © 2009 Elsevier Ltd All rights reserved.
__________________
-Justin 1994 Football Injury 1997 Snow Skiing Injury Laminotomy L4/L5 (3.7.97--17 years old) 1999 & 2003 MVA (not at fault both times) Grade V Tears L4/L5 & L5/L6 2-Level ProDisc® L4/L5 & L5/L6* *lumbosacral transitional vertebra (11.15.03--23 years old) Dr. Rudolf Bertagnoli -- dr-bertagnoli.com Pain-free for the last 4.5 yrs. 5.14.09 DSS with Dr. B. I'm here to help. Only checking PMs currently. |
|
|||
This looks promising. I have been taking antibiotics one hour before dental procedures since my 4 level ADR Surgery in November 2006. My dentist does this for all of his implant patients for three years after the surgery. I hardly ever take any antibiotics, due to the possibility of becoming resistant to them, but, this is some prevention that I do prescribe to.
Terry Newton
__________________
1980 ruptured L4-L5 1988 ruptured SI-L5 1990 ruptured C5-C6 1994 ruptured C6-C7 1995 Hemi-Laminectomy C5-C6, C6-C7 Mayo Clinic Bicycle Accident 2004 MRI, EMG, Facet Injections, Epidural Blocks, Lumbar Discogram. Stenum Hospital Surgery November 4, 2006 Prestige Disc C5-C6, C6-C7 Maverick Disc S1-L5, L4-L5 |
|
|||
Antibiotics before dental?
This is news to me. I am today 3 weeks post-op for 2 level Prodisc-C by Dr. Bertagnoli. I am doing great at this point. I saw this post about the prophylactic ABs and wonder what the reasoning is as it relates to prostheses in the spine. I am scheduled for some minor dental work in the near future, including replacing a temporary crown with a permanent one-after finishing up my Invisalign process shortly. (Had I known I'd be getting a nice scar on my neck I wouldn't have made my teeth so straight and white as it will only draw attention to my face and neck, lol-vanity will get you in trouble!)
I don't think my dentist would know what to do either way... |
|
||||
interesting...
interesting...
__________________
C4-5: Mild disc height loss with central annular fissure. Small broad-based left paracentral disc protrusion. Moderate central canal stenosis-the disc protrusion abuts and mildly flattens the left ventral surface of the spinal canal. C5-6: Disc desiccation with mild height loss.Diffuse discosteophyte bulge and uncovertebral joint hypertrophy, moderate central canal stenosis- Severe neuroforaminal stenosis bilaterally, right greater than left. |
Bookmarks |
|
|